Logo

Guidelines For The Treatment Of
Pulmonary Arterial Hypertension (PAH)

According to the 2015 ESC/ERS guidelines on pulmonary hypertension, the overall treatment goal in patients with PAH is to achieve or maintain a low-risk status, which is usually associated with good exercise capacity, good quality of life, good right ventricle function and a low mortality risk.[1] Patients at low risk have been shown to have the best outcomes.[2]

Regular comprehensive risk assessment of PAH patients is recommended to evaluate patients’ risk status and escalate therapy if required.[1]

uptravi-guidelines-graphs_-10

Adapted from Galiè et al. 2016[1]
CCB, calcium channel blocker; DPAH, drug-induced pulmonary arterial hypertension; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology; FC, functional class; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; IV, intravenous; PAH, pulmonary arterial hypertension; PDE-5, phosphodiesterase type 5; WHO, World Health Organization

Escalation to triple combination therapy is recommended when the initial treatment approach with double combination therapy results in an intermediate risk status.[1]

UPTRAVI® is the only drug with a class I recommendation for early sequential combination with an ERA and/or a PDE-5i.[1]

uptravi-guidelines-graphs_-11_2

Adapted from Galiè et al. 2016[1]
ERA, endothelin receptor antagonist; FC, functional class; PDE-5i, phosphodiesterase type-5 inhibitor; WHO, World Health Organization

Learn More About Uptravi®

Patient Management

Advice on how to manage your UPTRAVI® patients, including details on dosage and side effects.

Product Overview

A synopsis of the key benefits of UPTRAVI® in the treatment of PAH.

References

Galiè N et al. Eur Heart J 2016; 37:67–119.
Boucly A et al. Eur Respir J 2017; 50:1700889.
EM- 50402